ProFound Therapeutics said the Gates Foundation will invest up to $35 million to identify proteins, drug targets, and drug candidates for preeclampsia and eclampsia. The program uses ProFoundry and focuses on proteins expressed in placenta and serum samples, aiming to support biomarker development and an AI-enabled preeclampsia/eclampsia tool. The funding includes an initial $20 million and comes as maternal health remains an area with limited therapeutics and underdiagnosis. ProFound will also generate biomarkers and candidate targets drawn from its approach to the expanded proteome, including proteins produced outside canonical genome regions. For biotech developers, the package underscores how major philanthropy is increasingly backing platform-driven discovery rather than late-stage clinical development, seeking earlier scientific leverage in high-unmet-need disease areas.